Golimumab

drugbox-mab


source = Human
target = TNFα
CAS_number = 476181-74-5
ATC_prefix =
ATC_suffix =
PubChem =
DrugBank =
C=6530 | H=10068 | N=1752 | O=2026 | S=44
molecular_weight =
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Golimumab (CNTO 148) is a human monoclonal antibody which is used as an immunosuppressive drug. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule.

Golimumab was developed by Centocor and is being tested as a subcutaneous injection in phase III clinical trials for treatment of rheumatoid arthritis and will be marketed by Schering-Plough in Europe.Fact|date=April 2008 Johnson & Johnson, the parent company of Centocor, has requested approval from European Medicines Agency for the use of golimumab as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. [ [http://sev.prnewswire.com/retail/20080415/NYTU07615042008-1.html Johnson & Johnson Reports 2008 First-Quarter Results] ]

References